Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

White matter alterations in early Parkinson's disease: role of motor symptom lateralization.

Pelizzari L, Di Tella S, Laganà MM, Bergsland N, Rossetto F, Nemni R, Baglio F.

Neurol Sci. 2019 Oct 24. doi: 10.1007/s10072-019-04084-y. [Epub ahead of print]

PMID:
31650438
2.

Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Bergsland N, Tavazzi E, Schweser F, Jakimovski D, Hagemeier J, Dwyer MG, Zivadinov R.

CNS Drugs. 2019 Sep 25. doi: 10.1007/s40263-019-00668-6. [Epub ahead of print]

PMID:
31556017
3.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

Radiology. 2019 Nov;293(2):424-433. doi: 10.1148/radiol.2019190306. Epub 2019 Sep 24.

4.

Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.

Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C, Weinstock-Guttman B.

Mult Scler Relat Disord. 2019 Sep 9;36:101388. doi: 10.1016/j.msard.2019.101388. [Epub ahead of print]

PMID:
31525628
5.

re: Reliability of 3D Texture Analysis: A Multicenter MRI Study of the Brain.

Bergsland N.

J Magn Reson Imaging. 2019 Sep 11. doi: 10.1002/jmri.26923. [Epub ahead of print] No abstract available.

PMID:
31507009
6.

Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis.

Fuchs TA, Benedict RHB, Bartnik A, Choudhery S, Li X, Mallory M, Oship D, Yasin F, Ashton K, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Hum Brain Mapp. 2019 Dec 15;40(18):5231-5241. doi: 10.1002/hbm.24768. Epub 2019 Aug 24.

PMID:
31444887
7.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Ann Clin Transl Neurol. 2019 Sep;6(9):1757-1770. doi: 10.1002/acn3.50872. Epub 2019 Aug 22.

8.

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

Ziliotto N, Zivadinov R, Baroni M, Marchetti G, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Straudi S, Manfredini F, Ramanathan M, Bernardi F.

Eur J Neurol. 2019 Aug 13. doi: 10.1111/ene.14058. [Epub ahead of print]

PMID:
31408242
9.

Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.

Murali N, Browne RW, Fellows Maxwell K, Bodziak ML, Jakimovski D, Hagemeier J, Bergsland N, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

Eur J Neurol. 2019 Aug 1. doi: 10.1111/ene.14055. [Epub ahead of print]

PMID:
31369181
10.

Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D.

Neurology. 2019 Aug 6;93(6):e611-e623. doi: 10.1212/WNL.0000000000007892. Epub 2019 Jul 8.

PMID:
31285398
11.

Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R.

J Neuroimaging. 2019 Sep;29(5):615-623. doi: 10.1111/jon.12650. Epub 2019 Jul 1.

PMID:
31259467
12.

Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.

Fuchs TA, Benedict RH, Wilding G, Wojcik C, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605. [Epub ahead of print]

PMID:
31219390
13.

Combined Assessment of Diffusion Parameters and Cerebral Blood Flow Within Basal Ganglia in Early Parkinson's Disease.

Pelizzari L, Laganà MM, Di Tella S, Rossetto F, Bergsland N, Nemni R, Clerici M, Baglio F.

Front Aging Neurosci. 2019 Jun 4;11:134. doi: 10.3389/fnagi.2019.00134. eCollection 2019.

14.

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.

Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T Jr.

Mov Disord. 2019 Jul;34(7):1006-1013. doi: 10.1002/mds.27730. Epub 2019 Jun 10.

PMID:
31180615
15.

Corrigendum to "MR microneurography and quantitative T2 and DP measurements of the distal tibial nerve in CIDP" [Journal of the Neurological Sciences Volume 400, 15 May 2019, Pages 15-20].

Felisaz PF, Poli A, Vitale R, Vitale G, Asteggiano C, Bergsland N, Callegari I, Vegezzi E, Piccolo L, Cortese A, Pichiecchio A, Bastianello S.

J Neurol Sci. 2019 Aug 15;403:169. doi: 10.1016/j.jns.2019.05.035. Epub 2019 Jun 6. No abstract available.

PMID:
31178081
16.

Cerebrovascular reactivity and its correlation with age in patients with multiple sclerosis.

Pelizzari L, Laganà MM, Baglio F, Bergsland N, Cecconi P, Viotti S, Pugnetti L, Nemni R, Baselli G, Clerici M, Mendozzi L.

Brain Imaging Behav. 2019 Jun 7. doi: 10.1007/s11682-019-00132-5. [Epub ahead of print]

PMID:
31175576
17.

Aging and Brain Atrophy in Multiple Sclerosis.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10.

PMID:
31074192
18.

Cerebral blood flow and cerebrovascular reactivity correlate with severity of motor symptoms in Parkinson's disease.

Pelizzari L, Laganà MM, Rossetto F, Bergsland N, Galli M, Baselli G, Clerici M, Nemni R, Baglio F.

Ther Adv Neurol Disord. 2019 Mar 21;12:1756286419838354. doi: 10.1177/1756286419838354. eCollection 2019.

19.

MR microneurography and quantitative T2 and DP measurements of the distal tibial nerve in CIDP.

Felisaz PF, Poli A, Vitale R, Vitale G, Asteggiano C, Bergsland N, Callegari I, Vegezzi E, Piccolo L, Cortese A, Pichiecchio A, Bastianello S.

J Neurol Sci. 2019 May 15;400:15-20. doi: 10.1016/j.jns.2019.03.001. Epub 2019 Mar 11. Erratum in: J Neurol Sci. 2019 Aug 15;403:169.

PMID:
30878635
20.

Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.

Bergsland N, Ramasamy D, Tavazzi E, Hojnacki D, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2019 Apr;40(4):620-625. doi: 10.3174/ajnr.A6011. Epub 2019 Mar 14.

21.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.

22.

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.

Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.

AJNR Am J Neuroradiol. 2019 Mar;40(3):446-452. doi: 10.3174/ajnr.A5987. Epub 2019 Feb 28.

PMID:
30819766
23.

Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.

Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R.

J Neurol. 2019 Apr;266(4):866-875. doi: 10.1007/s00415-019-09208-0. Epub 2019 Feb 13.

PMID:
30758665
24.

Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.

Jakimovski D, Ramanathan M, Weinstock-Guttman B, Bergsland N, Ramasamay DP, Carl E, Dwyer MG, Zivadinov R.

Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667. [Epub ahead of print]

PMID:
30755085
25.

Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.

Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S.

J Comp Eff Res. 2019 Apr;8(5):305-316. doi: 10.2217/cer-2018-0135. Epub 2019 Feb 13.

26.

Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.

Jakimovski D, Benedict RH, Marr K, Gandhi S, Bergsland N, Weinstock-Guttman B, Zivadinov R.

Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608. [Epub ahead of print]

PMID:
30625030
27.

Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis.

Zivadinov R, Bergsland N, Dwyer MG.

Quant Imaging Med Surg. 2018 Nov;8(10):979-983. doi: 10.21037/qims.2018.11.01. No abstract available.

28.

Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?

Ziliotto N, Zivadinov R, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Ramanathan M, Marchetti G, Bernardi F.

Thromb Haemost. 2019 Jan;119(1):175-178. doi: 10.1055/s-0038-1676346. Epub 2018 Dec 31.

PMID:
30597511
29.

Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration.

Laganá MM, Mendozzi L, Pelizzari L, Bergsland NP, Pugnetti L, Cecconi P, Baselli G, Clerici M, Nemni R, Baglio F.

Curr Neurovasc Res. 2018;15(4):282-291. doi: 10.2174/1567202616666181123164235.

PMID:
30468125
30.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

31.

Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls.

Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F.

Neuroimage. 2019 Feb 1;186:308-320. doi: 10.1016/j.neuroimage.2018.11.011. Epub 2018 Nov 14.

PMID:
30445148
32.

Plasma levels of soluble NCAM in multiple sclerosis.

Ziliotto N, Zivadinov R, Jakimovski D, Baroni M, Tisato V, Secchiero P, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Bernardi F, Ramanathan M, Marchetti G.

J Neurol Sci. 2019 Jan 15;396:36-41. doi: 10.1016/j.jns.2018.10.023. Epub 2018 Oct 28.

PMID:
30412901
33.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
34.

Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.

Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R.

J Neurol Sci. 2018 Oct 15;393:128-134. doi: 10.1016/j.jns.2018.08.020. Epub 2018 Aug 23.

PMID:
30165291
35.

Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?

Jakimovski D, Topolski M, Kimura K, Marr K, Gandhi S, Ramasamy DP, Bergsland N, Hagemeier J, Weinstock-Guttman B, Zivadinov R.

Clin Auton Res. 2019 Jun;29(3):329-338. doi: 10.1007/s10286-018-0555-6. Epub 2018 Aug 17.

PMID:
30120624
36.

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Eur J Neurol. 2019 Jan;26(1):87-e8. doi: 10.1111/ene.13769. Epub 2018 Sep 3.

PMID:
30103277
37.

Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage.

Zivadinov R, Polak P, Schweser F, Bergsland N, Hagemeier J, Dwyer MG, Ramasamy DP, Baker JG, Leddy JJ, Willer BS.

J Head Trauma Rehabil. 2018 Sep/Oct;33(5):E24-E32. doi: 10.1097/HTR.0000000000000422.

38.

Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis.

Pelizzari L, Jakimovski D, Laganà MM, Bergsland N, Hagemeier J, Baselli G, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Sep;39(9):1703-1709. doi: 10.3174/ajnr.A5738. Epub 2018 Jul 26.

39.

Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zamboni P, Marchetti G, Zivadinov R, Ramanathan M.

Mult Scler Relat Disord. 2018 Oct;25:37-42. doi: 10.1016/j.msard.2018.07.009. Epub 2018 Jul 7.

PMID:
30031282
40.

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.

Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F.

Radiology. 2018 Nov;289(2):487-496. doi: 10.1148/radiol.2018180136. Epub 2018 Jul 17.

41.

Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.

Lin F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, Vaughn C, Gandhi S, Jakimovski D, Hulst HE, Benedict RH, Bergsland N, Fuchs T, Dwyer MG.

Mult Scler. 2019 Aug;25(9):1243-1254. doi: 10.1177/1352458518788218. Epub 2018 Jul 13.

PMID:
30004291
42.

Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study.

Fuchs TA, Carolus K, Benedict RHB, Bergsland N, Ramasamy D, Jakimovski D, Weinstock-Guttman B, Kuceyeski A, Zivadinov R, Dwyer MG.

AJNR Am J Neuroradiol. 2018 Aug;39(8):1480-1486. doi: 10.3174/ajnr.A5720. Epub 2018 Jul 5.

43.

Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study.

Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R.

Hum Brain Mapp. 2018 Oct;39(10):4007-4017. doi: 10.1002/hbm.24227. Epub 2018 Jun 19.

44.

Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2018 Sep;28(5):490-495. doi: 10.1111/jon.12527. Epub 2018 Jun 1.

PMID:
29856910
45.

Hemostasis biomarkers in multiple sclerosis.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Marchetti G, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Schweser F, Zamboni P, Ramanathan M, Zivadinov R.

Eur J Neurol. 2018 Sep;25(9):1169-1176. doi: 10.1111/ene.13681. Epub 2018 Jun 26.

PMID:
29758118
46.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
47.

Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.

Tavazzi E, Bergsland N, Cattaneo D, Gervasoni E, Laganà MM, Dipasquale O, Grosso C, Saibene FL, Baglio F, Rovaris M.

J Neurol. 2018 Jun;265(6):1393-1401. doi: 10.1007/s00415-018-8859-y. Epub 2018 Apr 7.

PMID:
29627940
48.

Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.

Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 May 15;388:175-181. doi: 10.1016/j.jns.2018.03.028. Epub 2018 Mar 17.

PMID:
29627017
49.

Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.

Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 Apr 15;387:152-156. doi: 10.1016/j.jns.2018.02.023. Epub 2018 Feb 10.

PMID:
29571854
50.

Establishing pathological cut-offs for lateral ventricular volume expansion rates.

Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R.

Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018.

Supplemental Content

Loading ...
Support Center